Some source checks need review. Dated summaries and references remain below. Confirm current guidance with the original source and your care team.
Thyroid questions need their own clinical context
The thyroid is another hormone system. The Endocrine Society statement discusses age-related thyroid measurements separately from overt thyroid disease. Persistent symptoms deserve clinical assessment in context, including medicines and health history. This is not a recommendation for everyone to buy a hormone panel or start treatment.
Sources: [1]
GH, sermorelin and related secretagogues
GH replacement for diagnosed deficiency is a different question from using GH-related products to slow aging. The Endocrine Society's 2023 statement distinguished treatment of diagnosed deficiency from anti-aging use and reported that studies in older people had not established benefits outweighing risks. Human CJC-1295 studies identified in this review measured short-term changes in GH and IGF-1 after injections. Those hormone measurements do not show longer life, preserved independence or other patient-important benefit. The studies of related molecules used different compounds and purposes; results should not be combined as if they tested one interchangeable treatment. Ask a qualified clinician about symptoms and evaluation rather than trying to raise a number or self-dose.
Menopause, testosterone and sexual-health symptoms
This source check needs review. Confirm current guidance and the exact product or care route with the original source before relying on this dated summary. This dated summary provides background on the comparison.
Dated source summary
Menopause is a normal life stage, and some people seek care for bothersome symptoms such as hot flashes or vaginal dryness. Menopause hormone therapy is a symptom-care decision with individual benefits, risks and alternatives. Testosterone evidence in older men also comes from selected groups with low measured levels and symptoms; those results do not establish a general energy, memory or longevity treatment for everyone as they age. Women’s menopause care and men’s testosterone evaluation are distinct clinical questions. Discuss persistent or concerning symptoms with a clinician, who can consider the likely cause, relevant history and options with you.
Where to go next
Sources and dates
The source date describes the original material; the review date records our check. A dated source summary is not continuous monitoring, product testing or confirmation of current purchase terms.
- [1]Hormones and Aging: An Endocrine Society Scientific Statement · Source date: 2023 · Reviewed
Narrative scientific statement, not an individual diagnosis rule; its conclusions concern anti-aging use and do not negate treatment of appropriately diagnosed GHD. It discusses agents/classes and does not establish efficacy of sermorelin, CJC-1295, or ipamorelin for patient-important longevity outcomes.
- [2]Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline · Source date: 2011 · Reviewed
Guideline is older and focused on adult GHD diagnosis and treatment. Not a source for current product compounding status or anti-aging efficacy.
- [3]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · Source date: 2006 · Reviewed
Small short-duration pharmacology studies; surrogate hormone endpoints; no evidence here of meaningful functional, disease, lifespan, or long-term safety outcomes. Abstract only, no full appraisal.
- [4]Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog · Source date: 2007 · Reviewed
Narrow population, short follow-up, surrogate endpoints, abstract only. Do not generalize to older adults or clinical outcomes.
- [5]Menopause: Medicines to Help You · Source date: Page date not stated in visible result; accessed 2026-11-03 · Reviewed
Consumer summary; not a substitute for clinician assessment or detailed prescribing guidance. Avoid implying all people with symptoms should take hormones.
- [6]The Menopause Society 2022 Hormone Therapy Position Statement release and highlights · Source date: 2022 · Reviewed
Summary of the 2022 statement and not a patient-specific treatment recommendation; exact applicability depends on individual history and current guidance.
- [7]Effects of Testosterone Treatment in Older Men · Source date: 2016 · Reviewed
Selected symptomatic low-testosterone male cohort; one-year follow-up; cannot support testosterone use in women, normal-testosterone men, or lifespan claims. Abstract-only review.
Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.
See a problem or outdated information? Tell us.